Skip to main content
Journal cover image

Advances and challenges: dendritic cell vaccination strategies for glioblastoma.

Publication ,  Journal Article
Schaller, TH; Sampson, JH
Published in: Expert Rev Vaccines
January 2017

Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15-17 months. This review provides an overview of recent advances in the field of glioblastoma immunotherapy. Areas covered: Recent advances in dendritic cell vaccination immunotherapy are showing encouraging results in clinical trials and promise to extend patient survival. In this report we discuss current scientific knowledge regarding dendritic cell (DC) vaccines, including approaches to differentiating, priming, and injecting dendritic cells to achieve maximal anti-tumor efficacy in glioblastoma. These findings are compared to recently completed and currently ongoing glioblastoma clinical trials. Novel methods such as 'fastDCs' and vaccines targeting DCs in-vivo may offer more effective treatment when compared to traditional DC vaccines and have already entered the clinic. Expert commentary: Finally, we discuss the challenges of T-cell dysfunctions caused by glioblastoma immunosuppression and how they affect dendritic cell vaccinations approaches.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Vaccines

DOI

EISSN

1744-8395

Publication Date

January 2017

Volume

16

Issue

1

Start / End Page

27 / 36

Location

England

Related Subject Headings

  • Virology
  • Treatment Outcome
  • Immunotherapy
  • Humans
  • Glioblastoma
  • Drug Discovery
  • Dendritic Cells
  • Clinical Trials as Topic
  • Cancer Vaccines
  • Brain Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schaller, T. H., & Sampson, J. H. (2017). Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert Rev Vaccines, 16(1), 27–36. https://doi.org/10.1080/14760584.2016.1218762
Schaller, Teilo H., and John H. Sampson. “Advances and challenges: dendritic cell vaccination strategies for glioblastoma.Expert Rev Vaccines 16, no. 1 (January 2017): 27–36. https://doi.org/10.1080/14760584.2016.1218762.
Schaller TH, Sampson JH. Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert Rev Vaccines. 2017 Jan;16(1):27–36.
Schaller, Teilo H., and John H. Sampson. “Advances and challenges: dendritic cell vaccination strategies for glioblastoma.Expert Rev Vaccines, vol. 16, no. 1, Jan. 2017, pp. 27–36. Pubmed, doi:10.1080/14760584.2016.1218762.
Schaller TH, Sampson JH. Advances and challenges: dendritic cell vaccination strategies for glioblastoma. Expert Rev Vaccines. 2017 Jan;16(1):27–36.
Journal cover image

Published In

Expert Rev Vaccines

DOI

EISSN

1744-8395

Publication Date

January 2017

Volume

16

Issue

1

Start / End Page

27 / 36

Location

England

Related Subject Headings

  • Virology
  • Treatment Outcome
  • Immunotherapy
  • Humans
  • Glioblastoma
  • Drug Discovery
  • Dendritic Cells
  • Clinical Trials as Topic
  • Cancer Vaccines
  • Brain Neoplasms